Table 5. In-hospital, early and long-term outcomes of study groups.
| Variable | Female arm (N = 169) (32.8%) | Male arm (N = 346) (67.2%) | CTO (+) (N=226) | ||||
|---|---|---|---|---|---|---|---|
| CTO(+) N =74 (43.8%) | CTO(-) N =95 (56.2%) | P | CTO(+) N = 152 (43.9%) | CTO(-) N = 194 (56.1%) | P | Female vs Male P |
|
| In-hospital outcomes | |||||||
| Death, % | 6.8 | 3.2 | 0.27 | 5.3 | 2.6 | 0.19 | 0.65 |
| Non-fatal MI, % | 2.7 | 2.1 | 0.80 | 1.3 | 2.1 | 0.60 | 0.46 |
| TVR, % | 2.7 | 2.1 | 0.80 | 3.9 | 2.1 | 0.30 | 0.63 |
| Bleeding, % | 4.0 | 7.4 | 0.36 | 2.0 | 2.6 | 0.71 | 0.36 |
| Stroke, % | 0.0 | 1.0 | 0.38 | 0.7 | 0.0 | 0.26 | 0.48 |
| Cardiogenic shock, % | 6.8 | 4.2 | 0.46 | 3.9 | 1.6 | 0.16 | 0.36 |
| Hospital stay, days (Q1-Q3) | 8 (5-10) | 7 (4-9) | 0.96 | 6 (4-8) | 5 (4-7) | 0.03 | 0.02 |
| Post-discharge outcomes | |||||||
| 30-days MACE, % | 16.2 | 8.4 | 0.12 | 13.8 | 7.2 | 0.04 | 0.63 |
| Death, % | 8.1 | 3.2 | 0.16 | 8.5 | 4.1 | 0.09 | 0.91 |
| Non-fatal MI, % | 5.4 | 4.2 | 0.72 | 3.9 | 3.1 | 0.67 | 0.62 |
| Revascularization in ACS, % | 4.0 | 4.2 | 0.96 | 5.3 | 3.1 | 0.31 | 0.69 |
| 12-month MACE, % | 33.8 | 27.4 | 0.37 | 29.6 | 21.1 | 0.07 | 0.52 |
| Death, % | 16.2 | 11.6 | 0.38 | 19.1 | 8.8 | 0.005 | 0.60 |
| Non-fatal MI, % | 14.9 | 15.8 | 0.87 | 9.9 | 11.9 | 0.56 | 0.27 |
| Revascularization in ACS, % | 12.2 | 13.7 | 0.77 | 9.9 | 10.8 | 0.77 | 0.60 |
| 24-month MACE, % | 40.5 | 32.6 | 0.29 | 37.5 | 28.9 | 0.09 | 0.66 |
| Death, % | 18.9 | 14.7 | 0.47 | 24.3 | 13.4 | 0.009 | 0.36 |
| Non-fatal MI, % | 20.3 | 16.8 | 0.57 | 13.2 | 13.4 | 0.94 | 0.16 |
| Revascularization in ACS, % | 13.5 | 15.8 | 0.68 | 12.5 | 12.9 | 0.91 | 0.83 |
ACS = acute coronary syndrome; MACE = major adverse cardiac events; MI = myocardial infarction; Q1-Q3 = quartile 1 and quartile 3; TVR = target vessel revascularization.